Qilu Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Explore linked clinical trials.126 results · Page 1 of 6
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer | gastric adenocarcinoma | Recruiting | Phase 2 | 2026-10-09 | NCT07867392 | |
| Comparative Study of QL1209 and Perjeta® in Healthy Male Participants | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 1 | 2026-10-09 | NCT07861139 | |
| A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Not yet recruiting | Phase 4 | 2026-10-02 | NCT07854522 | |
| The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia | Cancer Cachexia; Cancer Cachexia Syndrome | Recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT07735104 | |
| Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation | Cytopenia, Hemic and Lymphatic Diseases, blood platelet disease, hematologic disorder, thrombocytopenia | Not yet recruiting | Phase 2 | 2026-09-21 | NCT07829952 | |
| Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer | RAS Wild-type Metastatic Colorectal Cancer | Not yet recruiting | Phase 1 | 2026-09-21 | NCT07829588 | |
| A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma | Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 2 | 2026-09-18 | NCT07828873 | |
| Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-09-18 | NCT06954116 | |
| Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-09-15 | NCT07776080 | |
| Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction | Refractory or Relapsed Solid Tumors | Recruiting | Phase 1 | 2026-09-15 | NCT07620041 | |
| QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia | Cancer Treatment-Induced Thrombocytopenia | Recruiting | Phase 2 / Phase 3 | 2026-09-09 | NCT06456528 | |
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Not yet recruiting | Phase 3 | 2026-09-03 | NCT07802821 | |
| A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Not yet recruiting | Phase 1 | 2026-08-07 | NCT07751315 | |
| Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Not yet recruiting | Phase 2 | 2026-07-28 | NCT07730632 | |
| Phase II Study of QLC2519 in Pediatric Solid Tumor Participants | Cytopenia, Febrile Neutropenia, Hemic and Lymphatic Diseases, agranulocytosis, hematologic disorder, leukocyte disorder, leukopenia, neutropenia | Recruiting | Phase 2 | 2026-07-24 | NCT07724756 | |
| QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ | Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-07-21 | NCT07716449 | |
| An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-06-25 | NCT07667751 | |
| QLF4113 in Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 1 | 2026-06-09 | NCT07636707 | |
| QLC5508 in Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 3 | 2026-06-08 | NCT07632690 | |
| Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-06-08 | NCT07018050 | |
| A Phase 3 Clinical Study of QL2106 Injection | Plaque Psoriasis | Recruiting | Phase 3 | 2026-06-05 | NCT07511647 | |
| A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. | Adjuvant Therapy; Lymph Node Positive; TNBC | Recruiting | Not applicable | 2026-06-03 | NCT07622836 | |
| To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3) | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Not yet recruiting | Phase 2 | 2026-06-02 | NCT07620366 | |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | Advanced Prostate Cancer | Recruiting | Phase 1 / Phase 2 | 2026-06-02 | NCT07198633 | |
| Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients) | Diabetic Macular Edema (DME) | Not yet recruiting | Phase 4 | 2026-05-29 | NCT07612904 |